Azithromycin pharmacodynamics against persistent haemophilus influenzae in chronic obstructive pulmonary disease

Brian T. Tsuji, James Fisher, Raheal Boadi-Yeboah, Patricia N. Holden, Sanjay Sethi, Melinda M. Pettigrew, Timothy F. Murphy

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

The pharmacodynamic profile of azithromycin against persistent strains of nontypeable Haemophilus influenzae (NTHi) from chronic obstructive pulmonary disease (COPD) patients was characterized. Azithromycin displayed differential concentration-dependent activities (R 2 0.988); the pharmacodynamic response was attenuated when we compared the “first” and “last” strains of NTHi that persisted in the airways of the same patient for 819 days (the 50% effective concentration [EC 50 ] increased more than 50 times [0.0821 mg/liter versus 4.23 mg/liter]). In the hollow-fiber infection model, NTHi viability was maintained throughout simulated azithromycin (Zithromax) Z-Pak regimens over 10 days.

Original languageEnglish (US)
Article numbere01995
JournalAntimicrobial agents and chemotherapy
Volume62
Issue number2
DOIs
StatePublished - Feb 2018
Externally publishedYes

Bibliographical note

Publisher Copyright:
Copyright © 2018 American Society for Microbiology. All Rights Reserved.

Keywords

  • Azithromycin
  • Macrolide-lincosamide-streptogramin B
  • Nontypeable H. influenzae

Fingerprint

Dive into the research topics of 'Azithromycin pharmacodynamics against persistent haemophilus influenzae in chronic obstructive pulmonary disease'. Together they form a unique fingerprint.

Cite this